Genomenon Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
136
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$6.03M
- Investors
-
26
Genomenon General Information
Description
Developer of genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists in treating cancer and other heritable diseases, enabling physicians to improve patient outcomes.
Contact Information
Website
www.genomenon.comCorporate Office
- 206 East Huron Street
- Suite 114
- Ann Arbor, MI 48104
- United States
Corporate Office
- 206 East Huron Street
- Suite 114
- Ann Arbor, MI 48104
- United States
Genomenon Timeline
Genomenon Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Later Stage VC (Series B2) | 30-Jul-2026 | $6.03M | Completed | Generating Revenue | ||
| 15. Later Stage VC (Series B1) | 16-May-2024 | Completed | Generating Revenue | |||
| 14. Later Stage VC (Series B) | 25-Feb-2022 | Completed | Generating Revenue | |||
| 13. Grant | 15-Feb-2022 | Completed | Generating Revenue | |||
| 12. Secondary Transaction - Private | 01-Aug-2021 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series A) | 16-Mar-2021 | Completed | Generating Revenue | |||
| 10. Debt - PPP | 07-Apr-2020 | Completed | Generating Revenue | |||
| 9. Grant | 01-May-2019 | Completed | Generating Revenue | |||
| 8. Seed Round | 08-Jan-2019 | $2.5M | $6M | Completed | Generating Revenue | |
| 7. Seed Round | 07-Jul-2018 | $1.25M | $3.5M | Completed | Generating Revenue |
Genomenon Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | ||||||||
| Seed 1 | 1,303,131 | $0.000100 | $1.9 | $1.9 | 1x | $1.9 | 7.83% | |
| Seed | 1,590,190 | $0.000100 | $1.71 | $1.71 | 1x | $1.71 | 9.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Genomenon Comparisons
Industry
Financing
Details
Genomenon Competitors (22)
One of Genomenon’s 22 competitors is Scipher Medicine, a Venture Capital-Backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Scipher Medicine | Venture Capital-Backed | Waltham, MA | ||||
| Congenica | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Personal Genome Diagnostics | Formerly VC-backed | Baltimore, MD | ||||
| PierianDx | Private Equity-Backed | Creve Coeur, MO | ||||
| Foundation Medicine | Formerly VC-backed | Boston, MA |
Genomenon Patents
Genomenon Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4133109-A1 | Systems and methods for gene variant grouping and visualization | Pending | 10-Apr-2020 | ||
| EP-4133109-A4 | Systems and methods for gene variant grouping and visualization | Pending | 10-Apr-2020 | ||
| US-12712087-B2 | Systems and methods for gene variant grouping and visualization | Active | 10-Apr-2020 | ||
| US-20230298769-A1 | Systems and methods for gene variant grouping and visualization | Active | 10-Apr-2020 | G16B50/10 |
Genomenon Signals
Genomenon Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sorin Capital Funds | Venture Capital | Minority | ||
| Beringea | Venture Capital | Minority | ||
| P93 Ventures | Venture Capital | Minority | ||
| Spring Mountain Capital | Growth/Expansion | Minority | ||
| The 4100 Group | Venture Capital | Minority |
Genomenon Acquisitions (1)
Genomenon’s most recent deal was a Merger/Acquisition with Boston Genetics. The deal was made on 27-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Boston Genetics | 27-Jun-2023 | Merger/Acquisition | BPO/Outsource Services |
Genomenon FAQs
-
When was Genomenon founded?
Genomenon was founded in 2014.
-
Where is Genomenon headquartered?
Genomenon is headquartered in Ann Arbor, MI.
-
What is the size of Genomenon?
Genomenon has 136 total employees.
-
What industry is Genomenon in?
Genomenon’s primary industry is Decision/Risk Analysis.
-
Is Genomenon a private or public company?
Genomenon is a Private company.
-
What is the current valuation of Genomenon?
The current valuation of Genomenon is .
-
What is Genomenon’s current revenue?
The current revenue for Genomenon is .
-
How much funding has Genomenon raised over time?
Genomenon has raised $42.8M.
-
Who are Genomenon’s investors?
Sorin Capital Funds, Beringea, P93 Ventures, Spring Mountain Capital, and The 4100 Group are 5 of 26 investors who have invested in Genomenon.
-
Who are Genomenon’s competitors?
Scipher Medicine, Congenica, Personal Genome Diagnostics, PierianDx, and Foundation Medicine are some of the 22 competitors of Genomenon.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process